The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 170-175

  Wu, Yue ^a   Zhang, Weiping ^a   Liu, Weimin ^a   Zhuo, Xiaozhen ^a   Zhao, Zhao ^a   Yuan, Zuyi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Drug eluting stent; Mononuclear cells; Patients; Proinflammation

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IMPLANTATION; INFLAMMATION; MALE; METABOLIC PARAMETERS; MONONUCLEAR CELL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN DNA BINDING; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; DRUG-ELUTING STENTS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPID METABOLISM; MALE; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; SIROLIMUS; TREATMENT OUTCOME;

EID: 79952107428     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.007     Document Type: Article

References (29)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 3494:1315-1323.
2. Wilson G.J., Nakazawa G., Schwartz R.S., et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009, 120:141-149.
3. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents-Importance of delayed healing. Arterioscler Thromb Vasc Bio 2007, 27:1500-1510.
4. Anderson J.L., Adams C.D., Antman E.A. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). J Am Coll Cardiol 2008, 51:974-976.
5. Kushner F.G., Smith S.C., King S.B., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120:2271-2306.
6. Schiekofer S., Andrassy M., Chen J., et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappa B in PBMCs. Diabetes 2003, 52:621-633.
7. Ghanim H., Aljada A., Hofmeyer D., et al. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 110:1564-1571.
8. Haddy N., Sass C., Droesch S., et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003, 170(2):277-283.
9. Lee T.M., Lin M.S., Chang N.C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008, 101(4):530-535.
10. Bulcao C., Ribeiro F.F., Sanudo A., Ferreira S.G.R. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007, 7(3):219-224.
11. Heilbronn L.K., Noakes M., Clifton P.M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Bio 2001, 21(6):968-970.
12. Clerc T., Sbarra V., Domingo N., et al. Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol 1996, 118(7):1862-1868.
13. Poli A. Atoirvastatin-Pharmacological characteristics and lipid-lowering effects. Drugs 2007, 67:3-15.
14. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
15. Brown K., Park S., Kanno T., et al. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci US A 1993, 90:2532-2536.
16. Chiao P.J., Miyamoto S., Verma I.M. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci USA 1994, 91:28-32.
17. Budde L.M., Wu C., Tilman C., et al. Regulation of I kappa B beta expression in testis. Mol Biol Cell 2002, 13:4179-4194.
18. Malek S., Chen Y., Huxford T., et al. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J Biol Chem 2001, 276:45225-45235.
19. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma mediated effects in the vasculature. Circ Res 2008, 102:283-294.
20. Waite K.J., Floyd Z.E., Arbour-Reily P., et al. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J Biol Chem 2001, 276:7062-7068.
21. Harada K., Isse K., Kamihira T., et al. Th1 cytokine-induced downregulation of PPAR gamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 2005, 41:1329-1338.
22. Klotz L., Schmidt M., Giese T., et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005, 175:4948-4955.
23. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious?. Circulation 2004, 109:701-705.
24. Finn A.V., Nakazawa G., Ladich E., et al. Does underlying plaque morphology play a role in vessel healing after drug-eluting stent implantation?. JACC Cardiovasc Imaging 2008, 1:485-488.
25. Farb A., Weber D.K., Kolodgie F.D., et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002, 105:2974-2980.
26. Kozinski M., Krzewina-Kowalska A., Kubica J., et al. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis - comparison with stable and unstable angina. Inflamm Res 2005, 54:187-193.
27. Goldberg A., Zinder O., Zdorovyak A., et al. Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. Am Heart J 2003, 146:819-823.
28. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
29. Serruys P.W., Silber S., Garg S., et al. Comparison of Zotarolimus-eluting and everolimus-eluting Coronary stents. N Engl J Med 2010, 363:136-146.